Moving along the gradient, individuals with a high PRS but without major pathogenic variants represent a polygenic form of hypertriglyceridemia that responds partially to ANGPTL3 inhibition with evinacumab, reflecting preserved but inefficient lipolytic function [38,43]. The gene discussed is ANGPTL3; the disease is hypertriglyceridemia.